Ross Muken
Stock Analyst at Evercore ISI Group
(2.12)
# 2,951
Out of 4,980 analysts
46
Total ratings
60%
Success rate
1.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CRL Charles River Laboratories International | Maintains: Outperform | $180 → $190 | $156.70 | +21.25% | 8 | Aug 8, 2025 | |
HSIC Henry Schein | Maintains: In-Line | $78 → $70 | $68.73 | +1.85% | 10 | Aug 6, 2025 | |
ICLR ICON Public Limited Company | Maintains: Outperform | $170 → $240 | $172.38 | +39.23% | 9 | Jul 25, 2025 | |
A Agilent Technologies | Maintains: In-Line | $126 → $130 | $126.17 | +3.04% | 11 | Jul 2, 2024 | |
QGEN Qiagen | Downgrades: In-Line | n/a | $45.67 | - | 2 | Jul 16, 2019 | |
CAH Cardinal Health | Initiates: In-Line | $67 | $151.60 | -55.80% | 2 | Jan 5, 2018 | |
ILMN Illumina | Initiates: Outperform | $250 | $98.28 | +154.38% | 2 | Jan 4, 2018 | |
TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $490.13 | -55.11% | 1 | Jan 4, 2018 | |
MBLY Mobileye Global | Downgrades: In-Line | n/a | $14.02 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Aug 8, 2025
Maintains: Outperform
Price Target: $180 → $190
Current: $156.70
Upside: +21.25%
Henry Schein
Aug 6, 2025
Maintains: In-Line
Price Target: $78 → $70
Current: $68.73
Upside: +1.85%
ICON Public Limited Company
Jul 25, 2025
Maintains: Outperform
Price Target: $170 → $240
Current: $172.38
Upside: +39.23%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $126.17
Upside: +3.04%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $45.67
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $151.60
Upside: -55.80%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $98.28
Upside: +154.38%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $490.13
Upside: -55.11%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $14.02
Upside: -